ProKidney Q3 net loss widens to $42M; cash runway into Q4 2025

PROKIDNEY CORP.

Net loss $42.0M for Q3 2023 vs $33.9M for Q3 2022, driven by higher R&D costs.
Cash, equivalents and marketable securities $396.3M at Sep 30, down from $490.3M at Dec 31, 2022.
R&D expenses $32.2M in Q3 2023 vs $21.1M in Q3 2022, up 53% on clinical trial and staffing costs.
G&A expenses flat at $14.4M; equity-based compensation offset prior-year business combination costs.
Cash expected to fund operations into Q4 2025; 235.4M ordinary shares outstanding at Sep 30.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

PROKIDNEY CORP. reported financial results for the third quarter ended September 30, 2023.

Period: the third quarter ended September 30, 2023
Result: reported results

Exact text from the filing

On November 14, 2023, ProKidney Corp. issued a press release to announce its financial results for the quarter ended September 30, 2023.

View on SEC.gov

Browse all earnings releases →

PROKIDNEY CORP. filing history →

Source: SEC EDGAR

accession 0000950170-23-063326

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.